Notwithstanding promising clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from pharmacy benefit managers. Such insurers are often erecting obstacles to reimbursement, including high cost criteria and prior authorization that restrict user availability